phase 3 retatrutide III study demonstrates 30% weight loss Lilly orforglipron oral GLP-1 phase

But pharmaceutical chemistry has overcome similar challenges before, and the market incentive, a daily pill replacing complex injectable therapy for the world's most common chronic disease, ensures massive investment in solving these problems

Results showed modest improvements in insulin sensitivity and minor weight loss averaging 1-2 pounds

So thats such a valuable way to, I think, organize our biochemical thinking around that

Adverse events in the Phase 2 trial were consistent with the incretin drug class: nausea, vomiting, and diarrhea were the most common, predominantly mild to moderate and concentrated during dose titration